Publications

1. Arbyn M, Cuschieri K, Bonde J, Schuurman R, Cocuzza C, Broeck DV, et al. (2024). Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening. J Med Virol. 96(9):e29881. https://doi.org/10.1002/jmv.29881 PMID:39221498
2. Arbyn M, Rousta P, Bruni L, Schollin Ask L, Basu P (2024). Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. J Natl Cancer Inst. 116(6):775–8. https://doi.org/10.1093/jnci/djae042 PMID:38501990
3. Arroyo Mühr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, et al. (2024). Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun. 15(1):3679. https://doi.org/10.1038/s41467-024-47909-x PMID:38693149
4. Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, et al. (2024). A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial. Nat Med. 30(9):2596–604. https://doi.org/10.1038/s41591-024-03080-w PMID:38918630
5. Clifford GM (2024). Expanding the list of cancers recognized to be caused by infectious agents. J Natl Cancer Inst. 116(12):1875–7. https://doi.org/10.1093/jnci/djae185 PMID:39172647
6. Downham L, Rol ML, Forestier M, Romero P, Mendoza L, Mongelós P, et al. (2024). Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs. Int J Cancer. 155(5):816–27. https://doi.org/10.1002/ijc.34953 PMID:38602045
7. Downham L, Jaafar I, Rol ML, Nyawira Nyaga V, Valls J, Baena A, et al. (2024). Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. Br J Cancer. 130(4):517–25. https://doi.org/10.1038/s41416-023-02490-w PMID:37973957
8. Dusingize JC, Murenzi G, Muhoza B, Businge L, Remera E, Uwinkindi F, et al. (2024). Cancer risk among people living with human immunodeficiency virus (HIV) in Rwanda from 2007 to 2018. Int J Cancer. 155(12):2149–58. https://doi.org/10.1002/ijc.35091 PMID:39128948
9. Fuady A, Setiawan D, Man I, de Kok IMCM, Baussano I (2024). Toward a framework to assess the financial and economic burden of cervical cancer in low- and middle-income countries: a systematic review. JCO Glob Oncol. 10(10):e2400066. https://doi.org/10.1200/GO.24.00066 PMID:39116362
10. Guigon L, Sánchez LXG, Petit AS, Bonniec AL, Basu P, Rodrigue CM, et al. (2024). Would shared decision-making be useful in breast cancer screening programmes? A qualitative study using focus group discussions to gather evidence from French women with different socioeconomic backgrounds. BMC Public Health. 24(1):404. https://doi.org/10.1186/s12889-024-17876-5 PMID:38326802
11. Law CCY, Zhang L, Carvalho AL, Rabeneck L, Barkun AN, Nied-Kutterer A, et al. (2024). Canadian colorectal cancer screening programs: how do they measure up using the International Agency for Research on Cancer criteria for organized screening? J Can Assoc Gastroenterol. 7(4):312–8. https://doi.org/10.1093/jcag/gwae015 PMID:39139223
12. Mallafré-Larrosa M, Chandran A, Oswal K, Kataria I, Purushotham A, Sankaranarayanan R, et al.; ACCI Consortium (2024). Improving access to cancer care among rural populations in India: development of a validated tool for health system capacity assessment. Cancer Med. 13(14):e7343. https://doi.org/10.1002/cam4.7343 PMID:39039809
13. Malvi SG, Esmy PO, Muwonge R, Joshi S, Poli URR, Lucas E, et al. (2024). A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. J Natl Cancer Inst Monogr. 2024(67):317–28. https://doi.org/10.1093/jncimonographs/lgae042 PMID:39529521
14. Man I, Georges D, Basu P, Baussano I (2024). Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings. J Natl Cancer Inst Monogr. 2024(67):400–9. https://doi.org/10.1093/jncimonographs/lgae035 PMID:39529528
15. Mosquera I, Barajas CB, Theriault H, Benitez Majano S, Zhang L, Maza M, et al. (2024). Assessment of barriers to cancer screening and interventions implemented to overcome these barriers in 27 Latin American and Caribbean countries. Int J Cancer. 155(4):719–30. https://doi.org/10.1002/ijc.34950 PMID:38648380
16. Mrabti H, Sauvaget C, Bendahhou K, Selmouni F, Muwonge R, Lucas E, et al. (2024). Breast cancer treatment and its impact on survival in Morocco: a study over a decade. BMC Cancer. 24(1):786. https://doi.org/10.1186/s12885-024-12570-6 PMID:38956536
17. Rudzīte D, Vangravs R, Daugule I, Šķenders Ģ, Poļaka I, Vanags A, et al. (2024). Helicobacter pylori antibacterial resistance patterns in Latvia: results from the GISTAR pilot study. Microbiota Health Dis. 6:e1000. https://doi.org/10.26355/mhd_20246_1000
18. Selmouni F, Bendahhou K, Sauvaget C, Abahssain H, Lucas E, Muwonge R, et al. (2024). Impact of clinical breast examination-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco. Cancer. 130(19):3353–63. https://doi.org/10.1002/cncr.35419 PMID:38837217
19. Singini MG, Muchengeti M, Sitas F, Chen WC, Combes JD, Waterboer T, et al. (2024). Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status. Int J Cancer. 155(2):251–60. https://doi.org/10.1002/ijc.34919 PMID:38577820
20. Wei F, Georges D, Man I, Baussano I, Clifford GM (2024). Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 404(10451):435–44. https://doi.org/10.1016/S0140-6736(24)01097-3 PMID:39097395